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Background: Radical chemo-radiotherapy (CRT) is an effective organ-sparing treatment option for patients with locally
advanced head and neck cancer (LAHNC). Despite advances in treatment for LAHNC, a significant minority of these
patients continue to fail to achieve complete response with standard CRT. By constructing a multi-modality functional
imaging (FI) predictive biomarker for CRT outcome for patients with LAHNC we hope to be able to reliably identify
those patients at high risk of failing standard CRT. Such a biomarker would in future enable CRT to be tailored to the
specific biological characteristics of each patients’ tumour, potentially leading to improved treatment outcomes.
Methods/design: The INSIGHT study is a single-centre, prospective, longitudinal multi-modality imaging study using
functional MRI and FDG-PET/CT for patients with LAHNC squamous cell carcinomas receiving radical CRT. Two cohorts
of patients are being recruited: one treated with, and another treated without, induction chemotherapy. All patients
receive radical intensity modulated radiotherapy with concurrent chemotherapy. Patients undergo functional imaging
before, during and 3 months after completion of radiotherapy, as well as at the time of relapse, should that occur
within the first two years after treatment. Serum samples are collected from patients at the same time points as the
FI scans for analysis of a panel of serum markers of tumour hypoxia.
Discussion: The primary aim of the INSIGHT study is to acquire a prospective multi-parametric longitudinal data set
comprising functional MRI, FDG PET/CT, and serum biomarker data from patients with LAHNC undergoing primary
radical CRT. This data set will be used to construct a predictive imaging biomarker for outcome after CRT for LAHNC.
This predictive imaging biomarker will be used in future studies of functional imaging based treatment stratification
for patients with LAHNC. Additional objectives are: defining the reproducibility of FI parameters; determining robust
methods for defining FI based biological target volumes for IMRT planning; creation of a searchable database of
functional imaging data for data mining. The INSIGHT study will help to establish the role of FI in the clinical
management of LAHNC.
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Head and neck cancer (HNC) is the fifth most common
cancer worldwide [1]. Most HNC patients receive multi-
modality therapy combining surgery, radiotherapy and
chemotherapy in an attempt to eradicate disease whilst
preserving organ function. At least 50 % of HNC patients
present with stage III/IV disease, defined as locally
advanced head and neck cancer (LAHNC) [1]. In these
patients, there has been a shift away from surgery towards
organ-preserving treatment protocols involving concomi-
tant cisplatin-based chemo-radiotherapy [2]. When com-
pared to surgical treatment, chemo-radiotherapy delivers
equivalent, or better, loco-regional control and disease-
free survival, but with significantly improved functional
outcomes [2, 3].
Despite advances in treatment techniques, LAHNC
continues to have disappointing 5-year disease-free and
overall survival rates of 30–40 % [1]. Strategies to im-
prove outcomes by escalating conventionally-delivered
radiotherapy and/or cytotoxic chemotherapy appear at-
tractive but pose significant risks of severe acute and late
normal tissue damage and threaten chronic structural,
cosmetic and functional deficits that will have a significant
negative impact on quality of life [4–6]. Importantly,
recent technological developments in physical targeting of
radiation delivery, including intensity-modulated and
image-guided radiotherapy, now offer a means of select-
ively escalating dose to tumour tissue without exceeding
normal tissue tolerances [7, 8].
Biological studies have recently characterised LAHNC as
a disease spectrum, divisible into different prognostic
groups, based on demographic (tobacco exposure), clinical/
radiological (T and N stage) and molecular pathological
(HPV status) variables [9]. We can now look beyond the
standard model in which all patients receive treatment ac-
cording to a “one size fits all” philosophy. We can, instead,
look forward to rational treatment individualisation accord-
ing to biologically defined prognostic risk stratification. To
achieve this, we require the ability to stratify patients with
LAHNC by means of predictive biomarkers, which would
ideally provide reliable information about the likely impact
of a specific therapeutic intervention [10]. Predictive bio-
markers that rely on tissue biopsies are limited by sampling
bias due to intra-tumour heterogeneity [11, 12]. In contrast,
functional imaging techniques offer the possibility of char-
acterising much more completely, the spatio-temporal het-
erogeneity of tumours, in terms of parameters that are
known to have biological significance, such as those charac-
terising tumour perfusion, oxygenation, and metabolism
[13, 14]. By using functional imaging techniques, it may be
possible to identify specific areas of intrinsic radio-
resistance within tumours, and use these areas as targets
for radiation dose-escalation [8, 15–17]. Alternatively, func-
tional imaging parameters measured at baseline and duringearly treatment may be able to function as reliable bio-
markers for treatment response prediction and allow for
subsequent treatment selection [14, 18–21].
A common theme in published studies of functional
imaging techniques in HNC is a lack of consensus as to
how best to analyse the resulting data to extract clinic-
ally relevant signals pertaining to the tumour and its re-
sponse (or otherwise) to treatment [14, 22–24]. A yet
more complex question is how best to combine data and
parameters from different functional imaging modalities
to maximise the combined predictive power of these
techniques [14, 24, 25]. The goal of functional imaging
predictive biomarker studies is to identify patients for
specific treatment strategies in order to improve treat-
ment outcomes. In LAHNC, such strategies could in-
clude: radiotherapy dose escalation to specific tumour
volumes (e.g. hypoxia) identified on functional imaging,
treatment with specific targeted drugs e.g. anti-EGFR
therapy [26–28] or DNA repair inhibitors [29–31], or
treatment de-escalation in the case of patients with
favourable functional imaging profiles [32, 33].
Treatment response assessment using functional im-
aging requires that an observed change in a parameter
during or after treatment be greater than the intrinsic
variability of the parameter in the absence of treatment.
In the absence of treatment, HNC tumour size usually
changes relatively slowly, and is reproducibly measurable
[34]. By contrast, the physiologically dependent parame-
ters measured by functional imaging techniques, such as
perfusion, oxygenation, and glucose metabolism are
intrinsically dynamic and are known to fluctuate, over
varying timescales, in the absence of therapy [14]. An
additional source of significant functional imaging par-
ameter variability in HNC is the size and anatomical lo-
cation of the primary tumour and the extent of regional
lymph node metastases. These sources of variation have
not typically been taken into account in published studies
of functional imaging in HNC.
A further uncertainty is the optimal timing of functional
imaging scans during the course of radical chemo-
radiotherapy. A prospective study of 20 patients undergo-
ing radical chemo-radiotherapy within the Head and Neck
(H&N) Unit at The Royal Marsden Hospital (RMH) used
weekly CT scanning during radiotherapy looked at tumour
volume changes during treatment [34]. This study showed
that the most significant changes in tumour volume dur-
ing chemo-radiotherapy had already occurred by the end
of the second week of radiotherapy [34]. A subsequent
prospective pilot study of functional imaging in 10 pa-
tients undergoing radical chemo-radiotherapy within the
H&N Unit at RMH showed that there are substantial
changes in tumour tissue functional MRI and 18 F-fluoro-
deoxyglucose (FDG) PET/CT parameters after two cycles
of induction chemotherapy, before radiotherapy has begun
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aging study, 7 achieved a complete metabolic response on
FDG-PET/CT following two cycles of induction chemo-
therapy prior to starting radiotherapy. There were also sig-
nificant reductions in the dynamic contrast-enhanced
MRI (DCE-MRI) parameters (IAUGC60, and Ktrans), and
a significant increase in the diffusion weighted imaging
(DWI) apparent diffusion coefficient (ADC) parameter
over the same period [35]. These results from our pilot
study suggest that functional imaging data needs to be
gathered early in the course of treatment for LAHNC, if
important differences in tumour response to treatment
are not to be missed. Additional findings supporting early
data acquisition during treatment come from a prospect-
ive longitudinal study of serial 18 F-fluoromisonidazole
(FMISO) PET/CT in 25 patients with LAHNC undergoing
radical chemo-RT without induction chemotherapy [21].
This study found that FMISO-PET parameters derived
from scans after 1 and 2 weeks of chemo-RT week had the
strongest association with local-progression-free-survival.
There are numerous technical difficulties in characteris-
ing tumour hypoxia using FMISO-PET [36] and it would
be preferable to find alternative, simpler, and less costly
hypoxia imaging methods. Intrinsic susceptibility-weighted
MRI exploits the paramagnetic properties of deoxyhaemo-
globin in erythrocytes to create contrast and may be able to
provide rapid imaging of tumour hypoxia with high spatial
resolution. Deoxyhaemoglobin creates magnetic susceptibil-
ity perturbations around blood vessels and the transverse
MR relaxation rate R2* (R2* = 1/T2*) of water in blood and
the surrounding tissues increases in proportion to tissue
deoxyhaemoglobin concentration [37, 38]. Deoxyhaemoglo-
bin, therefore, is an intrinsic (endogenous), blood oxygen-
ation level–dependent (BOLD) contrast agent. Because
oxygenation of haemoglobin is proportional to arterial
blood polarographic oxygen levels and, therefore, in equilib-
rium with tissue polarographic oxygen levels, tumour R2* is
a sensitive index of tissue oxygenation and a surrogate
marker of hypoxia [37]. BOLD-MRI has often been used
together with an oxygen challenge [38], but this adds com-
plexity to the scanning process, and may not be tolerable as
part of a multi-modality functional MRI protocol. However,
there are now data which suggest that useful information
may still be obtained from BOLD-MRI images even in the
absence of an oxygen challenge [39, 40].
The feasibility of using biological tumour volumes
(BTVs) defined from functional MRI as targets for
intensity-modulated radiotherapy (IMRT) dose escalation
has been investigated in our pilot study of longitudinal
functional imaging during radical chemo-IMRT for
LAHNC [35]. Patients in this study received two cycles of
induction chemotherapy (IC) prior to definitive radical
chemo-radiation. Multi-parametric functional imaging
including DCE and DWI showed marked biologicalresponses making it difficult, or even impossible, to delin-
eate small volume residual disease during radiotherapy
planning and delivery following IC. Based on these data,
such BTV boost volumes would have to be defined on the
original baseline images acquired before IC. However, the
physical and biological relevance of such BTVs, at the start
of CRT, following 2 cycles of IC, is far from clear. The
findings from our pilot study contrast with other studies in
which FI was acquired during CRT without prior IC
[18, 41–48]. In those studies, untreated tumour was visible
on FI modalities at the outset of CRT and it was possible to
implement adaptive radiotherapy strategies in treatment
planning and phase 1 studies [44, 46, 49].
Following on from our pilot study of longitudinal func-
tional imaging for radical chemo-IMRT for LAHNC [35],
we have developed a successor study, termed INSIGHT
(functIonal imagiNg for defining biological radiotherapy
target volumeS, assessing disease response, and predIcting
loco-reGional control in patients undergoing cHemo-
radioTherapy for head and neck cancer). The INSIGHT
study is gathering longitudinal multi-parametric func-
tional imaging from two expanded cohorts of patients
with LAHNC. The principal aim of the INSIGHT study is
to develop a predictive functional imaging biomarker for
response to chemo-IMRT treatment for LAHNC. Such a
longitudinal functional imaging biomarker could be used
as the basis of treatment selection for patients with
LAHNC in future clinical trials aiming to personalise
treatment by directing patients towards specific treatment
protocols and interventions determined by the behaviour
of their tumour during treatment.
Methods/design
Study organisation and funding
The INSIGHT study was designed through collaboration
between the Head and Neck Unit and Dept. of Radiology
of the Royal Marsden Hospital, and the Division of Radio-
therapy and Imaging of the Institute of Cancer Research.
The study sponsor is The Royal Marsden Hospital NHS
Foundation Trust. All study investigations including FDG-
PET/CT, functional MRI, and chemo-IMRT are undertaken
within the Royal Marsden Hospital, London and Sutton.
The study is funded in part by grants from Cancer Research
UK (C46/A10588 and C7224/A1340), and additional fund-
ing is received via the NCRI H&N CSG. The study has
received institutional review board approvals from the
RMH Committee for Clinical Research (CCR study number
3926) and the National Research Ethics Committee (REC
number 13/LO/0067). The study complies with the declar-
ation of Helsinki, the British Good Clinical Practice (GCP)
regulations, and the UK Data Protection Act. The study has
been adopted into the NCRI Head and Neck Cancer
research portfolio (NCRI UKCRN 13860) and is listed on
the publicly accessible NCRI research study database.
Welsh et al. Radiation Oncology  (2015) 10:112 Page 4 of 11Study design and patient population
INSIGHT is a prospective longitudinal observational co-
hort study at a single cancer centre, across two sites, of
patients with locally advanced squamous cell carcinoma of
the head and neck, receiving definitive primary treatment
with radical chemo-IMRT. Patients may be treated with
or without induction chemotherapy. All patients undergo
serial 18 F-FDG PET/CT and multi-parametric functional
MRI (DCE, DWI, and BOLD) before, during, and
3 months after completion of treatment (Fig. 1). Serum
samples are also collected from patients at the time of
each MRI scan. The serum will be used to measure the
concentrations of a panel of serum markers of tumour
hypoxia that have been shown to be relevant to treatment
outcomes for LAHNC [50]. Circulating tumour DNA
levels could also potentially be measured from the study
serum samples, which may offer complementary data to
assist in differentiating the responses of patient’s tumours
to treatment [51, 52].
The study workflows for patients treated with and
without induction chemotherapy are shown in Fig. 1. In
addition to the scans at the time points shown in Fig. 1,
patients with loco-regionally recurrent disease occurring
within the first two years after treatment will undergo re-
peat 18 F-FDG PET/CT and multi-parametric functional
MRI. The majority of loco-regional recurrences following
treatment for LHANC occur in the first 2 years following
treatment [53, 54], and recurrent disease occurring later
than two years after primary treatment may represent a
second primary cancer. For this reason follow-up imagingFig. 1 Timelines for INSIGHT study functional imaging (FI) scans before, du
receiving two cycles of induction chemotherapy (IC) prior to primary radica
scans: DCE-MRI, DW-MRI, BOLD-MRI, FDG-PET/CT at each time point, excep
receiving primary radical chemo-radiotherapy (CRT) alone. For this group, F
FDG-PET/CT at each time point. For both groups repeated pre-treatment b
tests for FBC and serum markers of hypoxia will be taken on the same daywithin the INSIGHT study is limited to recurrences occur-
ring within two years of the end of primary chemo-
radiotherapy.
Inclusion criteria for the INSIGHT study are
1. Patients with documented histologically proven
squamous cell carcinoma of the head and neck
planned for primary radical chemo-radiotherapy,
with or without induction chemotherapy followed
by radiotherapy with concomitant platinum based
chemotherapy.
2. Age > 18 years.
3. World Health Organisation (WHO) performance
status 0 – 2.
4. Written informed consent.
Exclusion criteria for the study are
1. WHO performance status >2.
2. Patients with any previous malignancy apart from
non-melanoma skin cancer.
3. Patients with contraindications to MRI scanning.
4. Patients with contraindications to IV contrast
agents.
5. Patients with renal failure [estimated or measured
EDTA glomerular filtration rate (GFR) below
60 ml/min/1.73 m2].
6. Pregnancy or lactation.
7. Patient refusal.ring, and after radical chemo-radiotherapy. (a) Timing of FI for patients
l chemo-radiotherapy (CRT). For this group, FI consists of the following
t during CRT when FDG-PET/CT is omitted. (b) Timing of FI for patients
I consists of the following scans: DCE-MRI, DW-MRI, BOLD-MRI,
aseline FI scans will be performed in a proportion of patients. Blood
as each of the FI scans
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The principal aim of the INSIGHT study is to construct
a risk scoring system based on functional imaging
parameters to predict a patient’s response to radical
chemo-radiotherapy and their probability of obtaining
loco-regional disease control. This will be achieved by
comparing changes in functional MRI and FDG-PET/CT
parameters per patient in responders vs. non-responders
as defined by clinical evidence of residual disease 3 months
after completion of treatment. Secondary objectives are to:
1. Define reproducibility of the DCE, DWI, and BOLD
MRI measurements for this study population.
2. To look for evidence of a stable functional imaging
derived radiotherapy target volume (biological target
volume) that could be subject to radiotherapy dose
escalation.
3. To validate identified biological target volumes by
means of comparison of functional imaging findings
at baseline and during treatment with those at the
time of relapse.
4. To explore correlation of serum levels of hypoxia
biomarkers, and FI parameters before, during, and
after radical chemo-radiotherapy.
5. To generate a database of functional and anatomical
imaging for patients with head and neck cancers for
evaluation of new radiotherapy strategies and
planning techniques. The database will be explored
using data mining techniques to look for novel
patterns in functional imaging parameters across
patients that may be of biological and clinical
relevance [24].
Chemotherapy
All patients are treated according to RMH Head and
Neck Unit institutional protocols [7, 55, 56]. Patients re-
ceiving induction chemotherapy, are treated with either
2 cycles of TPF (docetaxel 75 mg/m2 day 1, cisplatin
75 mg/m2 day 1, 5-FU 750 mg/m2 days 1–4) or 2 cycles
of CF (cisplatin 75 mg/m2 day1, 5-FU 1000 mg/m2 days
1–4). Concomitant chemo-IMRT is given with cisplatin
100 mg/m2 on days 1 and 29 of IMRT. For patients with a
contraindication to cisplatin (EDTA GFR < 50 ml/min;
hearing loss; tinnitus) carboplatin (AUC = 5) is substituted
[57], but TPF is only given to patients able to receive
cisplatin.
IMRT
Patients undergo radiotherapy treatment planning in
accordance with the protocols of the RMH Head and Neck
Unit [53, 54]. After thermoplastic mask immobilisation a
contrast-enhanced CT scan of the head and neck is
obtained. Standard inverse planning techniques are used to
plan treatment using either fixed field IMRT or VMATaccording to the preference of the treatment planner and
treating clinician. Treatment plans are developed using
either the Eclipse (Varian Medical Systems, Palo Alto,
USA) or Pinnacle (Philips Radiation Oncology Systems,
Fitchburg, USA) treatment planning systems. FDG PET/
CT and functional MRI data are not used for target delin-
eation or dose prescription in this study. A dose of 65Gy in
30 fractions over 6 weeks is prescribed to the primary
tumour PTV and involved lymph node levels, and 54Gy in
30 fractions over six weeks is prescribed to prophylactically
treated regions. Tolerance doses of the brain stem, spinal
cord, and optic apparatus are not exceeded. Parotid gland
doses are minimised where feasible. Treatment is delivered
on an outpatient basis, unless patients require hospital
admission for supportive care.
18 F-FDG PET/CT
PET/CT studies are acquired using either a Gemini
PET/CT (Philips, The Netherlands) or a Biograph mCT
S128 (Siemens, Erlangen, Germany). Patients are asked
to fast for at least 4 h before the study. 18 F-FDG
(400 MBq) is injected intravenously if the blood sugar
level is < 10 mmol/L. Patients rest for 60 min prior to
PET/CT acquisition. Patients are positioned on a flat top
couch and immobilised using a thermoplastic mask to
match the position used for radiotherapy delivery. Emis-
sion data are acquired from the base of skull to carina.
Unenhanced CT is performed from the base of skull to
carina for purposes of attenuation correction and image
fusion for anatomical localization. Quantitative image ana-
lysis of PET/CT data will be performed using Hermes
[Hermes Medical Solutions, Stockholm, Sweden], and in-
house software.
Functional MRI
All functional MRI examinations are performed using
clinical 1.5 T MRI scanners (Aera, Siemens Medical Solu-
tions, Erlangen, Germany). As for PET/CT, patients are
positioned to match the position used for radiotherapy de-
livery. A flat top MRI couch is used with an appropriate
head rest and thermoplastic shell immobilisation. A single
multi-channel phased array flexible coil is used to provide
anterior coverage of the anatomy of interest (Fig. 2), whilst
spine-array coils built-in to the couch provide posterior
anatomical coverage. Non-contrast anatomical imaging is
obtained first in order to assess the extent of the disease
and aid functional MRI planning. Subsequently, and prior
to contrast injection (in order to avoid changes in tissue
relaxation), BOLD and DWI sequences are acquired over
the volume of interest. The DCE-MRI sequence is ob-
tained with bolus contrast injection (0.2 mL/kg body
mass, Dotarem, Guerbet, France).
Functional MRI data will be processed using in-house
software including the MRI Workbench (MRIW) [58], as
Fig. 2 INSIGHT study MRI patient set up (photograph shows one of
the study authors during study design and testing). Study patients
are positioned on a flat top MRI couch using the same baseplate,
neck rest, shoulder rest, and thermoplastic mask as used for
radiotherapy treatment planning and delivery. A single multi-channel
phased array flexible coil placed over the thermoplastic mask is used
to provide anterior coverage of the anatomy of interest, whilst spine-
array coils built-in to the couch provide posterior coverage. This set up
allows for rapid patient positioning and MRI data acquisition in the
radiotherapy treatment position which facilitates subsequent image
co-registration with longitudinal MRI scans as well as with CT and
PET/CT data
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Matlab [The MathWorks, Inc., Natick, Massachusetts,
United States]. Functional parameter maps (eg. Ktrans,
ADC, R2*) will be exported in the DICOM format for
use in radiotherapy treatment planning systems (Pinnacle,
Philips Radiation Oncology Systems, Fitchburg, USA, and
RayStation, RaySearch, Stockholm, Sweden).
Analysis of blood samples
A panel of chemokines, cytokines and growth factors that
have been shown to be associated with treatment out-
comes for patients with LAHNC [Byers et al. [50], will be
quantified for the isolated serum sample using a multiplex
bead assay. Following Byers et al. [50], a panel of serum
proteins will be measured at each study time point includ-
ing: Eotaxin, Osteopontin, VEGF, IL-1β, IL-4, IL-8, IL-10,
IL-12, IL-18, IFN-α, Gro-α, SDF-1α, FGF-1, TNF-α, TGF-
β, PDGF, GCSF, HGF, MIF-1 and Leptin. Complete blood
count analysis will be performed and haematocrit value
used for DCE-MRI processing.
Clinical follow-up
Following completion of treatment, patients will be
followed up in accordance with standard practice within
the RMH Head and Neck Unit. Patients undergo clinical
examination including flexible nasendoscopy and contrast
enhanced CT imaging of the head and neck 3 months fol-
lowing completion of treatment to determine therapeuticefficacy. Patients with evidence of residual or recurrent
disease at this point will be deemed to have failed treat-
ment, irrespective of whether or not they may be suitable
for surgical salvage. Patients are subsequently seen at
RMH for study specific follow-up on a 6-monthly basis
for the first two years after treatment, in addition to stand-
ard clinical follow-up. Patients with evidence of relapse
within the first two years undergo repeat FDG PET/CT
and functional MRI, as for the other study time points.
Evaluation of local response
Local response to chemo-IMRT is judged clinically, on
examination, including flexible nasendoscopy. Radio-
logical response is assessed on contrast enhanced CT
according to RECIST criteria. Any patient with evidence
of residual disease at 3 months post treatment will be
deemed to have failed treatment and will considered for
surgical salvage.
Data handling, storage, and archiving
All imaging and radiotherapy data will be anonymised,
coded and securely stored in a custom research PACS
database built from the Extensible Neuroimaging Archive
Toolkit (XNAT) open source imaging informatics plat-
form [59, 60]. The XNAT system will be used to identify
and retrieve image sets required for multimodality image
co-registration, outlining of BTV ROIs (RT planning sta-
tion) and functional imaging processing (MRIW, Matlab).
The study data processing flow is illustrated in Fig. 3. All
clinical data will be stored in accordance with British GCP
regulations. The data will be kept under the custody of the
PI with access only to authorised staff. Study documenta-




Response prediction Multiple logistic regression ana-
lyses will be performed to test the independence of
established clinical factors for the prediction of clinical
complete remission at 3 months following completion of
chemo-radiotherapy. Continuous variables (functional
imaging parameters such as Ktrans, ADC, R2*, SUVmax)
determined from DCE-MRI, DWI, BOLD-MRI, and
FDG-PET/CT will be included in the initial multivariate
model. Multivariable Cox regression analysis will be
used to explore the relationship between functional im-
aging parameters and progression free survival (PFS)
and overall survival (OS).
In order to determine which parameter or combination of
parameters best predicts clinical response after chemo-
radiotherapy, patients will be split (2:1) into a training set
on which to build a predictive model, and a smaller test
Fig. 3 INSIGHT study data processing pathways. Anatomical and functional image data are acquired using RMH clinical systems and backed up
on to the RMH clinical picture archiving and storage system (PACS). Anonymised image data are transferred electronically from the clinical PACS
to a dedicated research PACS system, based on XNAT [56, 57]. Data are extracted from XNAT for subsequent processing, such as the generation
of functional imaging parameter maps, and the results are stored within the same XNAT database. The XNAT system can communicate with the
radiotherapy treatment planning systems (RTPS) that are used for multi-modality image co-registration and region-of-interest (ROI) volume definition.
Voxel-wise functional image data from ROIs are extracted from image data using an RTPS and stored in XNAT from which they are then retrieved for
subsequent statistical analysis
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tic (ROC) curves for the prediction of residual disease
after radical chemo-radiotherapy will be generated to
determine cut-off values that yield optimal sensitivity and
specificity. The differences in sensitivity, specificity, posi-
tive predictive value, negative predictive value, and accur-
acy will be compared using the McNemar test.
Other outcomes
Reproducibility of FI parameters Reproducibility will
be assessed using the Bland-Altman method [61–63].
Two pre-treatment baseline scans per patient will be
compared. Absolute differences in a given functional im-
aging parameter between baseline scans are plotted
against the mean of the two parameter measurements
and reported as % change or absolute change depending
on whether or not variability is independent of size of
the measurement. If % change is more appropriate, the
coefficient of variation (CV) will be calculated (half the
absolute difference divided by the mean of the param-
eter) and mean and 95 % confidence limits for CV pre-
sented. If absolute change is more appropriate, limits of
agreement (LoA) with confidence intervals (CI) will be
reported showing the magnitude below which 95 % of
differences can be expected to lie.Response assessment A repeated-measures multivariate
analysis of variance (MANOVA) test will be used to pro-
vide a comparison of pre-, intra-, and post-treatment
levels of functional imaging parameters at each time
point. This will allow us to determine if there are signifi-
cant differences in the changes in the functional imaging
parameters during treatment in patients achieving
complete response at 3 months and those with residual
disease at that point.
Biological target volume Cluster analysis methods will
be applied to the functional imaging data to identify dis-
tinct sub-volumes within primary tumours and involved
lymph nodes (BTVs). These methods will be applied to
each of the distinct imaging modalities separately. We will
look at consensus BTVs across each of the functional im-
aging modalities. These BTVs will be imported in to the
radiotherapy treatment planning system to assess the
coverage of the BTVs by the treatment dose distribution.
We will explore the feasibility of radiotherapy dose escal-
ation to identified BTVs by means of radiotherapy plan-
ning studies. To help validate BTVs identified on baseline
and intra-treatment functional imaging scans, these BTVs
will be correlated with the location and volume of loco-
regional failure in patients who relapse during follow-up.
Welsh et al. Radiation Oncology  (2015) 10:112 Page 8 of 11Serum markers There is a lack of published literature
on change in levels of cytokines and growth factors dur-
ing the course of radical chemo-radiotherapy in patients
with LAHNC, and therefore this aspect of the study will
be exploratory. Distributions of serum marker variables
according to baseline factors, and correlations between
markers and functional imaging parameters will be
assessed with exact non-parametric tests (Wilcoxon,
Fisher, and Spearman). The levels of the serum markers of
hypoxia, functional imaging parameters will be compared
before, during, and after treatment using a multivariate re-
peated measures ANOVA test (MANOVA), after testing
the data for normality.
Functional imaging database All data gathered during
this study will be stored within a single XNAT database.
Known clinical characteristics with prognostic signi-
ficance (e.g. HPV status), data derived from the meas-
urement of serum markers of hypoxia, and data on
outcomes following treatment will be stored in the
XNAT database and associated with the stored scans
for each patient. This will allow the database to be
queried for ROIs with specific functional imaging char-
acteristics to be associated with specific clinical features
and treatment outcomes.
There will therefore be five data types per patient within
the XNAT database:
1. potential prognostic variables (demographic and
clinical variables that may influence outcome e.g.
TNM stage, HPV status, smoking status, age, sex)
2. anatomical imaging data (CT and MRI) and the
planned radical radiotherapy dose distribution
3. functional imaging data and associated parameters
derived from these scans (e.g. Ktrans, ve, kep,
IAUGC60 and T1 from DCE-MRI; ADC values
from DWI; R2* values from BOLD MRI; SUV
values from FDG-PET/CT)
4. clinical outcomes (response to treatment at
3 months post-RT, 2-year PFS and 2-year OS)
5. serum concentration of tumour hypoxia markersFig. 4 Response to induction chemotherapy and primary radical-chemoradio
Unit at RMH from January 2001 to September 2006. Data taken from (Bhide e
CR: complete response; PR: partial response; SD: stable disease)By storing all anatomical and functional imaging data
together with data on known clinical characteristics,
serum makers of hypoxia, and treatment outcomes, we
will create a unique database that can be interrogated to
look for novel associations between parameters that are
associated with adverse treatment outcomes. This data-
base will enable us to generate new hypotheses regarding
functional imaging parameters and outcomes in HNC.
Number of patients
Outcomes for patients with locally advanced HNC receiv-
ing standard treatment with induction chemotherapy and
radical chemo-radiotherapy within the H&N Unit at RMH
have been published [55]. These data show that after 2 cy-
cles of induction chemotherapy, 5.4 % achieve a complete
response (CR), 71.3 % a partial response (PR), and 23.3 %
stable disease (SD) (according to RECIST1.0 criteria)
(Fig. 4) [53]. Of those patients with PR and SD, 14.1 % and
46.7 % respectively will have clinical evidence of residual
disease following completion of radical chemo-radiother-
apy. Patients with residual disease after completion of
treatment underwent neck dissection, and this revealed
the presence of residual viable disease in 66.7 % [55]. Ac-
cording to these data, for every 100 LAHNC patients
treated using the standard RMH H&N Unit regimen
there will be 21 patients with clinical evidence of re-
sidual disease following completion of standard radical
chemo-radiotherapy (10 having had PR with induction
chemotherapy, and 11 having had SD). These are the
patients we wish to identify earlier in the course of
treatment by means of functional imaging in order to
deliver alternative/escalated treatment to improve their
treatment outcome.
Using functional imaging parameters derived from our
pilot study [35] we have calculated estimates for the mini-
mum numbers of patients required in order to be able to
detect statistically significant differences in the pre- and
post-chemotherapy values of Ktrans, ADC, and SUVmax
between patients responding and not-responding to treat-
ment. For a two-sided test at the 5 % significance level, for
treatment induced changes in imaging parameters of 40 %therapy for 129 patients with locally advanced HNC treated in the H&N
t al. [55]) [53]. (IC: induction chemotherapy; CRT: chemo-radiotherapy;
Welsh et al. Radiation Oncology  (2015) 10:112 Page 9 of 11(functional imaging responder) and 15 % (functional
imaging non-responder) respectively, and with standard
deviations for the imaging parameters of 30 % and 40 %
respectively, a total of 66 patients will be required for a
power of 80 % to predict response versus non-response on
individual functional imaging parameters. This study is
recruiting two such cohorts: one cohort of patients receiv-
ing induction chemotherapy, and another cohort of pa-
tients treated without induction chemotherapy.
Because this study obtains imaging data earlier during
the course of treatment than did our pilot study, and
also because of improvements in the imaging technol-
ogy used for this study, there is a degree of uncertainty
regarding the magnitude of the changes in functional
imaging parameters that we will observe. These consid-
erations mean that there is some uncertainty in the
required sample size that is difficult to quantify. An
interim data analysis (described below) will assist in
quantifying the magnitude of changes in functional
imaging parameters to be expected at each study time
point. It is acknowledged that the sample size may need
to be revised according to the results of this interim
analysis as well as according to the rate of complete
response to primary chemo-radiotherapy among re-
cruited patients.
Interim data analysis
An interim analysis will be undertaken after the first 10
patients have completed their scheduled study scans (up
to and including the 3 month post-treatment scans).
This will enable the relevance of the chosen scanning
time points to be assessed and amendments made, if it
appears that insufficient information is available from
scanning at any given time point. A threshold for the
minimum tumour volume of 0.63 cm3 has been derived
from our pilot study for the functional MRI scans [35].
This minimum volume allows for a signal to be obtained
from at least 20–40 voxels, which is a reasonable lower
limit on the basis of our pilot study data. If we find that
the average tumour volume for the first 10 patients at
any time point in the study is less than 0.63 cm3 then
the scans at that time point may be discontinued.
Discussion
By gathering functional imaging data from a sizable co-
hort of patients with LAHNC undergoing radical chemo-
radiotherapy we will build a database of tumours and their
biological characteristics, as determined from functional
imaging parameters. It may be possible to construct a
scoring system, based on a combination of standard
tumour characteristics and functional imaging parameters,
to make an early prediction of treatment response and the
probability of achieving loco-regional control after radical
chemo-radiotherapy. If we can establish such a reliablefunctional imaging predictive biomarker for HNC patients
we could use this to select patients for tailored treatments
as part of a future randomised biomarker study in which
patients were allocated to alternative treatments [64].
Such alternative treatments could include: intensification
or de-escalation by modulating radiotherapy dose and/or
by the addition or subtraction of concurrently delivered
drugs including targeted agents [8, 14].
Prospective longitudinal functional imaging studies are
essential to defining the place of these imaging tech-
niques in clinical practice [21, 35, 65]. Despite being
available as research tools for many years, functional im-
aging has yet to find a role within the standard clinical
management of LAHNC. Studies such as INSIGHT that
obtain data at multiple time points are needed to iden-
tify the optimal time points for distinguishing between
patients that will achieve success versus those that will
fail [21, 35]. Only then can rationally designed interven-
tional functional imaging biomarker studies be estab-
lished [14]. The INSIGHT study described here is an
important step towards undertaking such biomarker
driven interventional studies for patients with LAHNC.
Prospective longitudinal imaging studies do require sig-
nificant numbers of scans, as well as needing to recruit
significant numbers of patients, in order to achieve a
representative sample of the relevant patient population.
Ideally, such studies would be conducted at multiple
centres to facilitate rapid accrual of data, but there re-
main significant obstacles to performing multi-centre
functional imaging studies, particularly in relation to
DCE-MRI [66, 67]. These obstacles cannot be ignored if
functional imaging is to form a routine part of patient
management to permit treatment personalisation, as the
results of functional imaging studies will need to be gen-
eralisable across treatment centres. We hope to expand
the INSIGHT study into a multi-centre endeavour in
due course, to help to achieve the much sought after
goal of defining the utility of functional imaging in the
management of LAHNC. Interested investigators are
invited to contact the corresponding author.
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